DRG SUCCESSFULLY EXHIBITS AT MEDLAB DUBAI 2018!

Feb 28, 2018 | News | 0 comments

The DRG Group recently exhibited at the largest healthcare exhibition & congress in the Middle East: MEDLAB DUBAI from February 5 – 8, 2018 with great success!

In addition to the presentation of several new assays DRG offered live demonstrations of our fully automated random access analyzer: DRG:HYBRiD-XL®. Visitors from around the world gathered to receive personalized presentations of the Hybrid-XL instrument and DRG also displayed our newest ELISA kits like DHT-optimized (DiHydroTestosterone) and Hepcidin 25 (bioactive) High Sensitive ELISA kit.

Several new tests have been added to the DRG:Hybrid-XL in the past few months, including beta hCG, Free Estriol, and TM-CA 72-4. Development is ongoing to expand the Hybrid-XL test panel in the autoimmune segment.

The DRG Group thanks all attendees for their ongoing support and interest! If you are interested in becoming an authorized DRG:HYBRiD-XL® distributor in your territory, please contact Gregory Guest at [email protected] for more information.

Gregory C. Guest

Gregory C. Guest

Gregory C. Guest is the International Marketing Manager located at DRG International’s worldwide headquarters in Springfield, NJ.
Gregory C. Guest

News and Updates

Sign Up for Our Newsletter

  • By submitting this form, you are granting: DRG International, Inc., 841 Mountain Avenue, Springfield, NJ, 07081, permission to email you. You may unsubscribe via the link found at the bottom of every email. (See our Email Privacy Policy (http://constantcontact.com/legal/privacy-statement) for details.) Emails are serviced by Constant Contact.

Click the link to learn more about how DRG is certified in the manufacturing and distribution of in-vitro diagnostic reagents used in the diagnosis of autoimmune status, cancer, cardiac markers, disease status, fertility testing, pregnancy testing, diabetes and immune status.